

CSD/BM/SE/2025-2026  
 July 16, 2025

**To**  
**Department of Corporate Services**  
**BSE Limited**  
**25th Floor, P. J. Towers,**  
**Dalal Street, Mumbai - 400 001**

**To**  
**Listing Department**  
**National Stock Exchange of India Limited**  
**Exchange Plaza, Bandra Kurla Complex**  
**Bandra (E), Mumbai – 400 051**

**Scrip Code: 530239**

**Scrip Symbol: SUVEN**

Dear Sir/Madam,

**Sub: Outcome of the Meeting of Board of Directors of Suven Life Sciences Limited held on July 16, 2025 – Allotment of 91,86,490 Equity Shares of the Company on preferential basis upon conversion 91,86,490 fully paid warrants**

.....

With reference to subject and pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, we wish to inform that, the Board of Directors of the Company at its meeting held today i.e. Wednesday, July 16, 2025 has approved the conversion of 91,86,490 fully paid warrants and issued & allotted 91,86,490 (Ninety-one lakh Eighty-six Thousand Four Hundred and Ninety) Equity Shares of Rs.1/- each to the following Non-Promoter Persons/ Entities at an issue price of Rs. 134/- per share on preferential basis in accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Sl. No.	Non-promoter persons/entities	No. of Equity shares allotted
1.	QUANT MUTUAL FUND	47,01,490
2.	ABAKKUS DIVERSIFIED ALPHA FUND	29,85,000
3.	COBRA INDIA (MAURITIUS) LIMITED	15,00,000
	<b>Total</b>	<b>91,86,490</b>

Further we would like to inform that the Company has received from above said allottees 100% consideration amount aggregating to Rs. 1,23,09,89,660/- in compliance with SEBI (ICDR) Regulations, 2018.

**Consequently, the paid-up equity share capital of the company stands increased to the following:**

Particulars	No. of Equity Shares	Amount in INR
Pre-issue subscribed & paid-up capital	21,80,73,717	21,80,73,717.00
<b>Post-issue subscribed &amp; paid-up capital</b>	<b>22,72,60,207</b>	<b>22,72,60,207.00</b>

## Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
 Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713  
 Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com

Disclosure required pursuant to Regulation 30 and Schedule III of the SEBI (LODR) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is enclosed herewith as **Annexure A**.

We request you to take this on your records. The Board Meeting commenced at 1:30 P.M. and concluded at 2:35 P.M.

Thanking you.  
Yours faithfully,  
For **Suven Life Sciences Limited**

**Shrenik Soni**  
Company Secretary

Encl.: as above

**Annexure**

**Suven Life Sciences Limited**

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713  
Tel: 91 40 2354 1142/ 1152 Email: [info@suven.com](mailto:info@suven.com) website: [www.suven.com](http://www.suven.com)

**Details under amended Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Sl. no.	particulars	details											
a)	type of securities proposed to be issued (viz. equity shares, convertibles etc.);	Fully paid-up equity shares upon conversion of warrants											
b)	type of issuance (further public offering, rights issue, depository receipts (ADR/ GDR), qualified institutions placement, preferential allotment etc.);	Preferential Allotment in accordance with Chapter V of the SEBI ICDR Regulations and other applicable law.											
c)	total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately);	91,86,490 Equity Shares of face value of Rs. 1/- each pursuant to conversion of 91,86,490 warrants at an issue price of ₹ 134/- per warrant, for an aggregate consideration of Rs. 1,23,09,89,660/- to below allottees.											
d)	in case of preferential issue, the listed entity shall disclose the following additional details to the stock exchange(s):												
	i. number of investors;	3											
	ii. names of the investors;	<table><tr><th>Particulars</th><th>No. of Equity Shares allotted</th></tr><tr><td><b>Non-promoter persons/entities</b></td><td></td></tr><tr><td>QUANT MUTUAL FUND</td><td>47,01,490</td></tr><tr><td>ABAKKUS DIVERSIFIED ALPHA FUND</td><td>29,85,000</td></tr><tr><td>COBRA INDIA (MAURITIUS) LIMITED</td><td>15,00,000</td></tr></table>		Particulars	No. of Equity Shares allotted	<b>Non-promoter persons/entities</b>		QUANT MUTUAL FUND	47,01,490	ABAKKUS DIVERSIFIED ALPHA FUND	29,85,000	COBRA INDIA (MAURITIUS) LIMITED	15,00,000
	Particulars	No. of Equity Shares allotted											
	<b>Non-promoter persons/entities</b>												
	QUANT MUTUAL FUND	47,01,490											
	ABAKKUS DIVERSIFIED ALPHA FUND	29,85,000											
	COBRA INDIA (MAURITIUS) LIMITED	15,00,000											
	iii. post allotment of securities - outcome of the subscription	Pursuant to conversion, the issued, subscribed and paid-up equity share capital of the Company stands increased to Rs. 22,72,60,207/- consisting of 22,72,60,207 fully paid-up equity shares of Rs. 1/- each.											
	iv. issue price/ allotted price (in case of convertibles)	Rs. 134/- per share											
v. in case of convertibles - intimation on conversion of securities or on lapse of the tenure of the instrument;	Allotment of 91,86,490 equity shares pursuant to the conversion of warrants at an issue price of Rs. 134/- each (face value of Rs. 1/- each and premium of Rs. 133/- each) upon receipt of 100% consideration amount from above mentioned allottees amounting to Rs. 1,23,09,89,660/-.												
e)	any cancellation or termination of proposal for issuance of securities including reasons thereof.	Not applicable											

**Suven Life Sciences Limited**

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
 Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713  
 Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com